secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001651308-23-000107
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene terminates TIGIT inhibitor option pact with Novartis; regains full rights to ociperlimab
--------------------------------------------------------------------------------

- Mutual termination effective July 10, 2023; BeiGene Switzerland regains global rights to develop, manufacture and commercialize ociperlimab.
- Phase 3 AdvanTIG 302 trial of ociperlimab + tislelizumab for 1L NSCLC with high PD-L1 will continue enrollment.
- Phase 3 AdvanTIG 301 trial in stage III unresectable NSCLC discontinued due to changing treatment paradigm.
- Option agreement originally disclosed December 19, 2021; no financial terms of termination disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000107/0001651308-23-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130823000107/bgne-20230710.htm
  HTML page:      https://secwatch.observer/filing/0001651308-23-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer